Cargando…
Bryostatin‐1 ameliorated experimental colitis in Il‐10 (−/−) Mice by protecting the intestinal barrier and limiting immune dysfunction
Bryostatin‐1 (Bry‐1) has been proven to be effective and safe in clinical trials of a variety of immune‐related diseases. However, little is known about its effect on Crohn's disease (CD). We aimed to investigate the impact of Bry‐1 on CD‐like colitis and determine the mechanism underlying this...
Autores principales: | Zuo, Lugen, Li, Jing, Ge, Sitang, Ge, Yuanyuan, Shen, Mengdi, Wang, Yan, Zhou, Changmin, Wu, Rong, Hu, Jianguo |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6652299/ https://www.ncbi.nlm.nih.gov/pubmed/31251471 http://dx.doi.org/10.1111/jcmm.14457 |
Ejemplares similares
-
Spontaneous colitis in IL‐10‐deficient mice was ameliorated via inhibiting glutaminase1
por: Li, Jing, et al.
Publicado: (2019) -
Epac‐2 ameliorates spontaneous colitis in Il‐10
(−/−) mice by protecting the intestinal barrier and suppressing NF‐κB/MAPK signalling
por: Song, Xue, et al.
Publicado: (2021) -
Pygopus2 ameliorates mesenteric adipocyte poor differentiation to alleviate Crohn's disease ‐like colitis via the Axin2/GSK3β pathway
por: Li, Jing, et al.
Publicado: (2022) -
Mannose ameliorates experimental colitis by protecting intestinal barrier integrity
por: Dong, Lijun, et al.
Publicado: (2022) -
Adjudin-loaded redox-sensitive paclitaxel-prodrug micelles for overcoming multidrug resistance with efficient targeted Colon cancer therapy
por: Chen, Deli, et al.
Publicado: (2020)